Valuation: Verastem, Inc.

Market Cap 1.18B 1.06B 976M 884M 1.65B 112B 1.68B 11.64B 4.67B 59.17B 4.45B 4.35B 187B P/E 2026 *
-5.99x
P/E 2027 * -7.25x
Enterprise Value 996M 892M 821M 744M 1.39B 94.6B 1.42B 9.79B 3.93B 49.76B 3.74B 3.66B 157B EV / Sales 2026 *
8.95x
EV / Sales 2027 * 7.44x
Free-Float
99.19%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day+0.93%
1 week-2.89%
Current month+21.12%
1 month+21.12%
3 months+59.84%
6 months+78.57%
Current year+26.30%
1 week 9.34
Extreme 9.3416
10.25
1 month 6.7
Extreme 6.7
10.25
Current year 3.43
Extreme 3.43
10.25
1 year 3.43
Extreme 3.43
10.82
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
39.6
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 2023-07-31
Director of Finance/CFO 39 2022-10-30
Chief Tech/Sci/R&D Officer - 2024-04-17
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 2023-07-31
Director/Board Member 69 2017-05-02
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 Sell

Chief Financial Officer

-2,566 0.0042%
10/1/26 Sell

Chief Executive Officer

-44,121 0.0717%
9/21/26 Sell

Chief Financial Officer

-55 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+0.93%-2.89%+5.63%+56.75% 1.18B
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average +0.40%+6.50%+43.64%+191.37% 39.55B
Weighted average by Cap. +0.18%+5.42%+48.37%+185.74%

Financials

2026 *2027 *
Net sales 111M 99.68M 91.69M 83.08M 155M 10.57B 158M 1.09B 439M 5.56B 418M 409M 17.53B 159M 143M 131M 119M 222M 15.11B 226M 1.56B 628M 7.95B 597M 585M 25.07B
Net income -170M -153M -140M -127M -238M -16.18B -242M -1.67B -672M -8.51B -640M -626M -26.84B -179M -160M -147M -133M -249M -16.96B -254M -1.75B -704M -8.92B -670M -656M -28.13B
Net Debt -188M -169M -155M -141M -263M -17.88B -268M -1.85B -743M -9.4B -707M -692M -29.66B -
Projected Income Statement - Annual - Verastem, Inc.
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
26-10-30 $9.750 +0.93% 2,411,811
26-10-29 $9.660 -1.78% 1,939,759
26-10-28 $9.835 -2.62% 2,809,016
26-10-27 $10.10 +1.00% 4,708,399
26-10-26 $10.00 -0.40% 4,289,252
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Verastem, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
9.750USD
Average target price
17.11USD
Spread / Average Target
+75.50%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Verastem, Inc.
  1. Stock Market
  2. Stocks
  3. VSTM Stock